Candel Therapeutics Q3 EPS $(0.29) Misses $(0.19) Estimate
Portfolio Pulse from Benzinga Newsdesk
Candel Therapeutics reported Q3 losses of $(0.29) per share, missing the analyst consensus estimate of $(0.19) by 52.63 percent. However, this is a 3.33 percent increase over losses from the same period last year.
November 09, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Candel Therapeutics' Q3 earnings per share of $(0.29) missed the consensus estimate by 52.63%, but improved by 3.33% compared to the same period last year.
Candel Therapeutics reported a larger than expected loss for Q3, which is generally seen as negative by the market. However, the YoY improvement in losses might provide some positive sentiment. Overall, the impact is likely to be negative in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100